Bank of New York Mellon’s Bellerophon Therapeutics, Inc. BLPH Stock Holding History

Bank of New York Mellon’s Portfolio BLPH Stock Details BLPH Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2021 Q2	–	Sell	-11,583	Closed	-$60K	–	4558
2021 Q1	$60K	Sell	11,583 -561	-5%	-$3.91K	﹤0.01%	4234
2020 Q4	$81K	Sell	12,144 -503	-4%	-$4.12K	﹤0.01%	4105
2020 Q3	$128K	Buy	+12,647	New	+$149K	﹤0.01%	3931
2020 Q1	–	Sell	-11,378	Closed	-$60K	–	4239
2019 Q4	$60K	Hold	11,378	–	–	﹤0.01%	4088
2019 Q3	$82K	Hold	11,378	–	–	﹤0.01%	4055
2019 Q2	$102K	Sell	11,378 -280	-2%	-$2.68K	﹤0.01%	4028
2019 Q1	$114K	Sell	11,658 -2	-0%	-$22	﹤0.01%	3983
2018 Q4	$140K	Hold	11,660	–	–	﹤0.01%	3915
2018 Q3	$189K	Hold	11,660	–	–	﹤0.01%	3949
2018 Q2	$423K	Sell	11,660 -81	-0.7%	-$2.8K	﹤0.01%	3700
2018 Q1	$367K	Sell	11,741 -88	-0.7%	-$2.8K	﹤0.01%	3717
2017 Q4	$458K	Buy	+11,829	New	+$310K	﹤0.01%	3650

Other funds holding BLPH

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

Renaissance Technologies New York $63.9B AUM 45.56% 1-Year Est. Return

Wells Fargo San Francisco, California $530B AUM 22.01% 1-Year Est. Return

BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return

Telemetry Investments New York $63.3M AUM 0.06% 1-Year Est. Return

Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return

Northern Trust Chicago, Illinois $757B AUM 28.64% 1-Year Est. Return

ACM

ACT Capital Management Wayne, Pennsylvania $153M AUM

State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return

First Trust Advisors Wheaton, Illinois $170B AUM 46.21% 1-Year Est. Return

Bank of New York Mellon's BLPH Position: Q2 2021 in Review

Bank of New York Mellon sold out of Bellerophon Therapeutics, Inc. (BLPH) in Q2 2021, closing a stake of 11,583 shares — an estimated $60K sold.

Bank of New York Mellon first reported a position in BLPH in Q4 2017 and held it in 12 quarters. The position peaked at $458K in Q4 2017. 27 funds tracked by Wall St. Rank hold BLPH as of Q2 2021.

Bank of New York Mellon reported no remaining Bellerophon Therapeutics, Inc. position as of Q2 2021 after selling out during the quarter.
Bank of New York Mellon sold 11,583 Bellerophon Therapeutics, Inc. shares in Q2 2021, an estimated $60K.
Bank of New York Mellon first reported a position in Bellerophon Therapeutics, Inc. in Q4 2017 and held it in 12 quarters.
Bank of New York Mellon's Bellerophon Therapeutics, Inc. position peaked at $458K in Q4 2017.
27 funds tracked by Wall St. Rank held Bellerophon Therapeutics, Inc. as of Q2 2021.

Based on Bank of New York Mellon's 13F filing for Q2 2021, filed 11 Aug 2021.